Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31125791 | 1.00 | BTK (0.41) | BTKEPHX2PDE9AKMT2AMAPT | |
| SCHEMBL21903703 | 0.93 | CYP1A2 (0.38) | BTKEPHX2PDE9AKMT2AMAPT | |
| SCHEMBL20645567 | 0.92 | BTK (0.41) | BTKEPHX2PDE9AKMT2AMAPT | |
| SCHEMBL15913949 | 0.92 | BTK (0.41) | BTKEPHX2PDE9AKMT2AMAPT | |
| SCHEMBL15913950 | 0.92 | BTK (0.41) | BTKEPHX2PDE9AKMT2AMAPT | |
| SCHEMBL31684304 | 0.92 | BTK (0.41) | BTKEPHX2PDE9AKMT2AMAPT | |
| SCHEMBL31684324 | 0.92 | BTK (0.41) | BTKEPHX2PDE9AKMT2AMAPT | |
| SCHEMBL25230106 | 0.91 | KMT2A (0.42) | BTKPDE9AKMT2AMAPTDPP7 | |
| SCHEMBL30497632 | 0.91 | KMT2A (0.42) | BTKPDE9AKMT2AMAPTDPP7 | |
| SCHEMBL30813541 | 0.89 | BTK (0.46) | BTKPDE9ASRCABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | BTK 1/4885EPHX2 3025/4885PDE9A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.